15.75p 0.0 0.0%
Last Trade - 10/10/18
| Market Cap | £n/a |
| Enterprise Value | £n/a |
| Revenue | £22.0m |
| Position in Universe | th / 1803 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.90 | 3.78 | 5.67 | 9.85 | 18.7 | 22.0 | 26.8 | 34.9 | +41.3% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2022
|
31st Dec 2023
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups. It offers immunogenicity assessment, which includes EpiScreen, iTope and T Cell Epitope Database (TCED); antibody drug conjugates, which includes ThioBridge linkers; antibody, which includes Composite Human Antibodies and Composite Proteins; optimization of pharmacokinetics, which includes TheraPEG, HiPEG conjugates PEG to poly-histidine motifs and CyPEG, and PolyPEG; cell line development, which includes Composite Human Antibody; process development, Good manufacturing practices (GMP) manufacturing, and small molecules. The Company's Abzena inside includes Composite Human Antibodies and ThioBridge Antibody Drug Conjugates (ADCs).
| Last Annual | March 31st, 2018 |
| Last Interim | March 31st, 2018 |
| Incorporated | March 25, 2014 |
| Public Since | July 10, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | 236 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | London Stock Exchange |
| Shares in Issue | 214,893,379 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Babraham Hall Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom |
| Web | http://www.abzena.com/ |
| Phone | +44 1223 903498 |
| Contact | () |
| Auditors | James Cowper Kreston |
As of 10/10/18, shares in Abzena are trading at 15.75p, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.
Shares in Abzena are currently trading at 15.75p and the price has moved by -51.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abzena price has moved by -57.09% over the past year.
Of the analysts with advisory recommendations for Abzena, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Abzena is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Abzena is scheduled to issue upcoming financial results on the following dates:
Abzena does not currently pay a dividend.
Abzena does not currently pay a dividend.
Abzena does not currently pay a dividend.
To buy shares in Abzena you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Abzena are currently trading at 15.75p, giving the company a market capitalisation of £n/a.
Here are the trading details for Abzena:
We were not able to load our ranking data for Abzena
We were not able to load any forecast data for Abzena.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abzena. Over the past six months, the relative strength of its shares against the market has been -24.26%. At the current price of 15.75p, shares in Abzena are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Abzena.
We were unable to find the directors for Abzena.
Here are the top five shareholders of Abzena based on the size of their shareholding:
